| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 106,080 | 112,381 | ||
| Prepaid expenses and other current assets | 2,830 | 2,440 | ||
| Total current assets | 108,910 | 114,821 | ||
| Property and equipment, net | 20,823 | 20,563 | ||
| Total assets | 129,733 | 135,384 | ||
| Accounts payable and accrued expenses | 46,092 | 42,822 | ||
| Accrued development expense | 1,366 | 3,788 | ||
| Accrued compensation and benefits | 362 | 563 | ||
| Other current liabilities | 226 | 159 | ||
| Total current liabilities | 48,046 | 47,332 | ||
| Other non-current liabilities | 119 | 79 | ||
| Total liabilities | 48,165 | 47,411 | ||
| Common stock, 0.001 par value 120,000,000 shares authorized 48,307,896 and 48,203,179 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 48 | 48 | ||
| Additional paid-in capital | 565,065 | 560,663 | ||
| Retained earnings (accumulated deficit) | -483,545 | -472,738 | ||
| Total stockholders' equity | 81,568 | 87,973 | ||
| Total liabilities and stockholders' equity | 129,733 | 135,384 | ||
CASSAVA SCIENCES INC (SAVA)
CASSAVA SCIENCES INC (SAVA)